Page 3 - BrazilianPharmaceuticalindustryEng

The aim of our company in cooperation with the export department is, on the one hand, to create successful
strategic alliances and to become the partner of choice in offering services and innovative and branded generic
pharmaceutical products in the region of Latin America.

We believe in establishing long term business partnerships with local companies, distributors, producers and
workshops for products, services, and expertise you provide, both in the private markets, and at the level of
national and international competitions.

Export opportunities for Greek companies activated in the pharmaceutical and medical products industry "are
hiding" markets such as Latin America.

The Ministry of Health of Brazil, applying Productive Development Policy (PDP) for the transfer of technology in
government laboratories, enters into agreements with private companies so that those, within five years, are to
produce their own products contained at in the agreement. During this time the Ministry of Health guarantees
the exclusive supply of the product of a private company by the Unified Health System (SUS). After a lapse of
five years, the state laboratory independently continues the production in order to meet domestic market needs.

Private companies, which retain the patented product, must have developed or be holders of a license of the
technology transfer. They can be Brazilian or foreign, which, however, should ensure a percentage of
productive integration of the product development in the Brazilian territory. The agreement may include one or
more private companies. Requests for product development within the PDP are submitted by state laboratories
to which the transfer of technology is made.

As part of the PDP, the Brazilian Ministry of Health annually publishes a list of products of strategic importance
for the SUS, the development of which asks the government laboratories for proposals.

Decree 2.888 / 30.12.2014 setting out the strategic products for 2015 (drugs and active ingredients, medical
devices and materials) is available in the tables posted every year by the Ministry of Health:

In 2531 / 12.11.2014 Decree the mechanism of PDP agreements is fully described.

So far , 98 technology transfer processes are underway, involving 19 government laboratories and 55 private
companies. They are in relation with the production of 92 products, of which 61 medicines (27 bio-medicines),
19 health products, 5 devices and 6 vaccines. Of the 92, 26 have already been purchased by the Ministry of
Health for the SUS.

Additionally, according to a recent study of Commercial & Economic Affairs Office in Brazil, pharmaceutical
exports can take place, at least for original and unavailable in Brazil, generics.

But it is crucial that the appropriate choice of a local partner is ensured (importer / distributor), since the law
reserves for the last, advantage of exclusive commercial exploitation of the product for five years.

Regarding the purchase of raw materials, particularly the active ingredients, they present particular interest, as
most Brazilian pharmaceutical companies do not yet have expertise and infrastructure for the production of raw
materials used.

Address: Hub Office: Rua Jandaia, 130 Cep: 01316-100 Liberdade, Sao Paulo–SP - Brasil
Mobile Phone: +55 11960722628
Email: info@eurobrazilbusiness.com - Website: www.eurobrazilbusiness.com